9 completed. 9 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 9 |
| Phase 2 | 4 | Completed 4 |
Follow Desmoid Tumors: new trials by email Literature Review of Desmoid Tumors trials Research Report on Desmoid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor vactosertib/imatinib combination - Desmoid Tumor | Phase 1 / Phase 2 | Completed | Hyo Song Kim | 24 | 2019-04-15 | 2024-05-13 |
| Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059 Tegavivint - Desmoid Tumor | Phase 1 | Completed | Iterion Therapeutics | 24 | 2018-07-15 | 2023-03-01 |
| Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers Nab-Rapamycin, Nivolumab - Ewing Sarcoma, PEComa | Phase 1 / Phase 2 | Completed | Sarcoma Oncology Research Center, LLC | 34 | 2017-08-24 | 2025-02-17 |
| MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors Magnetic Resonance High Intensity Focused Ultrasound - Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors | Phase 1 | Completed | AeRang Kim | 7 | 2014-04-01 | 2025-01-01 |
| A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis Sirolimus - Desmoid Tumor | Phase 1 / Phase 2 | Completed | MaineHealth | 9 | 2014-02-01 | 2023-06-26 |
| Endoxifen in Adults With Hormone Receptor Positive Solid Tumors Z-Endoxifen - Hormone Receptor-Positive Breast, Gynecologic | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2011-03-01 | 2025-12-23 |
| Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate Imatinib mesylate, Cyclophosphamide (Dosing level 1 ), Imatinib mesylate, Cyclophosphamide (Dosing level 2), Imatinib mesylate, Cyclophosphamide (Dosing level 3) - Cancer | Phase 1 | Completed | Centre Oscar Lambret | 26 | 2009-02-09 | 2026-09-17 |
| Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis imatinib mesylate - Desmoid Tumor | Phase 1 / Phase 2 | Completed | UNICANCER | 40 | 2004-09-01 | 2016-08-30 |
| MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma entinostat - Cancer | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 75 | 2001-03-01 | 2012-03-15 |
Carcinoma, Hepatocellular (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Chordoma (2) · Endometrial Neoplasms (2) · Fallopian Tube Neoplasms (2) · Melanoma (2) · Neoplasms (2) · Osteosarcoma (2) · Sarcoma (2) · Sarcoma, Ewing (2) · Uveal Melanoma (2) · Wilms Tumor (2)
Fibroma (9) · Neoplasms by Histologic Type (9) · Neoplasms, Connective Tissue (9) · Neoplasms, Connective and Soft Tissue (9) · Neoplasms, Fibrous Tissue (9) · Neoplasms (7) · Neoplasms by Site (5) · Adenocarcinoma (4) · Carcinoma (4) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Neoplasms, Glandular and Epithelial (4) · Neoplasms, Nerve Tissue (4)
Imatinib Mesylate (2) · 4-hydroxy-N-desmethyltamoxifen (1) · Blood Specimen Collection (1) · Cyclophosphamide (1) · Nivolumab (1) · Sirolimus (1) · entinostat (1) · vactosertib (1)
AeRang Kim (1) · Centre Oscar Lambret (1) · Hyo Song Kim (1) · Iterion Therapeutics (1) · MaineHealth (1) · National Cancer Institute (NCI) (1) · National Institutes of Health Clinical Center (CC) (1) · Sarcoma Oncology Research Center, LLC (1) · UNICANCER (1)
United States (6) · France (2) · Canada (1) · South Korea (1)
Aaron R Weiss, DO (1) · AeRang Kim, MD, PhD (1) · Alice P Chen, M.D. (1) · Erlinda M Gordon, MD (1) · Jean-Yves Blay, MD, PhD (1) · Shivaani Kummar, MD (1)
PMID 20622000, PMID 24089446, PMID 31401903
2008 (1)